GLP-1 weight loss drugs may be misused by patients with eating disorders: Study

A new study highlights potential misuse of GLP-1 receptor agonists—such as semaglutide (Ozempic)—by individuals with eating disorders, who may use the drugs to sustain or exacerbate unhealthy weight loss patterns. Coverage emphasizes the dual-edged nature of these medications, originally prescribed for diabetes and obesity, now under scrutiny for their unintended risks in vulnerable populations. Outlets including *MedPage Today*, *ABC News*, and *Medical Republic* report on the findings, framing the issue as a growing public health alert.

The study, cited across multiple sources, suggests patients with eating disorders may self-administer GLP-1 drugs beyond medical supervision, despite their approval for weight management. Reports note the drugs’ mechanism—reducing appetite and promoting weight loss—could inadvertently reinforce disordered eating behaviors. Regulatory and clinical responses remain unspecified, though experts are urged to monitor prescribing practices closely.

Next steps may include updated guidelines for prescribing GLP-1 medications, expanded patient screening for eating disorder risk factors, and further research into long-term misuse patterns. Coverage does not yet specify regulatory actions or manufacturer responses.